MyFinsight
Home
Blog
About
TNGX_BIG
Tango Therapeutics, Inc. (TNGX)
TNGX_BIG
Tango Therapeutics, Inc. (TNGX)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$38,846K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Sales and maturities of marketab...
Proceeds from issuance of common...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Prepaid expenses and other curre...
Accretion on marketable securiti...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-55,342
-45,514
-38,749
-62,845
Depreciation
425
463
479
555
Noncash operating lease expense
988
972
958
973
Stock-based compensation
16,892
10,797
5,980
6,625
Accretion on marketable securities
-945
-1,124
-768
-560
Other, net
18
-21
19
1
Prepaid expenses and other current assets
5,192
2,299
-350
1,652
Other long-term assets
19
-10
13
-20
Accounts payable
-759
1,785
-1,231
-344
Accrued expenses and other liabilities
5,901
-8,690
4,488
1,604
Operating lease liabilities
-797
-781
-1,193
-245
Deferred revenue
-
-
0
-53,811
Net cash used in operating activities
-38,866
-44,360
-29,718
-30,952
Purchase of property and equipment
-20
-2
222
151
Sales and maturities of marketable securities
73,102
64,045
39,525
65,965
Purchases of marketable securities
519,095
54,412
175,020
18,337
Net cash (used in) provided by investing activities
-445,973
9,635
-135,717
47,477
Proceeds from issuance of common stock and pre-funded warrants
714,818
-
212,400
-
Proceeds from issuance of common stock upon exercise of stock options and purchase of shares under espp
-
-
7,012
2,541
Proceeds from at-the-market offerings, net of issuance costs
-
62,778
-
-
Payment of transaction costs
95
537
36
-
Proceeds from issuance of common stock under stock plans
20,624
17,605
-
-
Net cash provided by financing activities
672,569
79,846
219,376
2,541
Net change in cash, cash equivalents and restricted cash
187,730
45,121
53,941
19,066
Cash, cash equivalents and restricted cash, beginning of period
159,967
114,846
60,999
60,999
Cash, cash equivalents and restricted cash, end of period
347,697
159,967
114,846
60,905
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock and...
$714,818K
Proceeds from issuance of
common stock under...
$20,624K
Net cash provided by
financing activities
$672,569K
(115660.59%↑ Y/Y)
Canceled cashflow
$62,873K
Net change in cash,
cash equivalents and...
$187,730K
(1079.80%↑ Y/Y)
Canceled cashflow
$484,839K
something is missing
-$62,778K
Payment of transaction
costs
$95K
Sales and maturities
of marketable...
$73,102K
(76.84%↑ Y/Y)
Purchase of property and
equipment
-$20K
(-103.21%↓ Y/Y)
Stock-based compensation
$16,892K
(157.11%↑ Y/Y)
Accrued expenses and
other liabilities
$5,901K
(419.45%↑ Y/Y)
Noncash operating lease
expense
$988K
(-2.95%↓ Y/Y)
Depreciation
$425K
(-32.00%↓ Y/Y)
Net cash (used in)
provided by investing...
-$445,973K
(-2758.08%↓ Y/Y)
Net cash used in
operating activities
-$38,866K
(-6.43%↓ Y/Y)
Canceled cashflow
$73,122K
Canceled cashflow
$24,206K
Purchases of marketable
securities
$519,095K
(2068.68%↑ Y/Y)
Net loss
-$55,342K
(-42.44%↓ Y/Y)
Prepaid expenses and
other current assets
$5,192K
(367.75%↑ Y/Y)
Accretion on marketable
securities
-$945K
(-30.89%↓ Y/Y)
Operating lease
liabilities
-$797K
(2.09%↑ Y/Y)
Accounts payable
-$759K
(13.75%↑ Y/Y)
Other long-term
assets
$19K
(-93.81%↓ Y/Y)
Other, net
$18K
(1700.00%↑ Y/Y)
Buy us a coffee